Effect of Quality of Life Impact and Clinical Severity on Adherence to Topical Acne Treatment

Background: Topical medications are the most commonly prescribed treatments for acne patients. However, adherence to these treatments and possible associations with clinical severity and quality of life (QoL) impact are unclear. Purpose: We evaluated the association between sociodemographic factors, clinical severity, and QoL impact and adherence to topical acne treatments. Methods: This was an observational study of acne patients referred for usual care to community-based dermatologists. Adherence was assessed with questionnaires after 2 months of acne therapy. The associations of adherence with factors of interest were evaluated by chi-square analysis and Spearman rank correlation. Results: In 152 acne patients treated with topical medications, low adherence was observed in 26%, medium in 49%, and high in 24%. Age, gender, duration of acne, education level, third-party drug plan coverage, smoking history, recreational drug use, ingestion of alcohol, and number of prescribed topical agents were not significantly associated with adherence. Adherence was significantly positively correlated with QoL impact (r = .24, p = .003), with the role-emotional and self-perception domains having the highest correlations. In contrast, adherence was weakly negatively correlated with facial acne severity (r = .16, p = .047). Limitations: This study focused on facial acne, and adherence was based on patient reporting. Conclusions: Adherence to topical acne therapy increases with impact on QoL but decreases with increasing acne severity.

[1]  W. Gulliver,et al.  Development and Validation of a Comprehensive Acne Severity Scale , 2007, Journal of cutaneous medicine and surgery.

[2]  J. Strauss,et al.  Guidelines of care for acne vulgaris management. , 2007, Journal of the American Academy of Dermatology.

[3]  Jerry Tan,et al.  Condensation and validation of a 4-item index of the Acne-QoL , 2006, Quality of Life Research.

[4]  S. Feldman,et al.  Adherence in dermatology: A review of the last 20 years , 2006, The Journal of dermatological treatment.

[5]  W. Cunliffe,et al.  Objective assessment of compliance with treatments in acne , 2005, The British journal of dermatology.

[6]  W. Cunliffe,et al.  Guidelines for treating acne. , 2004, Clinics in dermatology.

[7]  Rajesh Balkrishnan,et al.  Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. , 2004, Journal of the American Academy of Dermatology.

[8]  H. Gollnick,et al.  Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. , 2003, Journal of the American Academy of Dermatology.

[9]  R. Nydegger,et al.  Factors related to patient compliance in the treatment of acne vulgaris , 2003, International journal of dermatology.

[10]  L. McLeod,et al.  Responsiveness of the Acne-Specific Quality of Life Questionnaire (Acne-QoL) to treatment for acne vulgaris in placebo-controlled clinical trials , 2002, Quality of Life Research.

[11]  G. Baliva,et al.  Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. , 2002, Archives of dermatology.

[12]  D. Thiboutot,et al.  Health‐related quality of life among patients with facial acne − assessment of a new acne‐specific questionnaire , 2001, Clinical and experimental dermatology.

[13]  R. Stern,et al.  Medication and medical service utilization for acne 1995-1998. , 2000, Journal of the American Academy of Dermatology.

[14]  W J Cunliffe,et al.  Prevalence of facial acne in adults. , 1999, Journal of the American Academy of Dermatology.

[15]  R. Stern Acne Therapy: Medication Use and Sources of Care in Office-Based Practice , 1996 .

[16]  B. Arroll,et al.  Prevalence of acne vulgaris in Auckland senior high school students. , 1995, The New Zealand medical journal.

[17]  J. Garioch,et al.  Acne in schoolchildren: no longer a concern for dermatologists. , 1989, BMJ.

[18]  H. Maibach Pharmionics in Dermatology , 2006, American journal of clinical dermatology.